|
Indian Pediatr 2010;47:
356-358 |
|
Response to Growth Hormone Therapy in
Adolescents with Familial Panhypopituitarism |
B Kulshreshtha, M Eunice, and AC Ammini
From Department of Endocrinology and Metabolism, All
India Institute of Medical Sciences, Delhi, India.
Correspondence to: Dr AC Ammini, Department of
Endocrinology and Metabolism, All India Institute of Medical Sciences,
Delhi, India.
Email: [email protected]
Received: May 8, 2008;
Initial review: May 28, 2008;
Accepted: March 12, 2009.
|
Abstract
Familial combined pituitary hormone deficiency is a
rare endocrine disorder. We describe growth patterns of four children (3
females and 1 male) from two families with combined pituitary hormone
deficiency. These children received growth hormone at ages ranging from
14.5 years to 19 years. While all the female siblings reached their
target height, the male sibling was much shorter than mid parental
height. The reasons for sexual dimorphism in growth patterns in these
children are unclear.
Key words: Familial, Growth hormone, Hypopituitarism.
|
F amilial combined pituitary hormone
deficiency is rare(1). Short stature is the most common clinical
manifestation of panhypopituitarism(1,2). We describe growth patterns in
children from two families with hypopituitarism initiated late on growth
hormone (GH) therapy.
Case Reports
Family 1: Two sisters aged 5 and 6
years, presented with complaints of short stature and poor height velocity
(2.5 cm/year). At 7 and 8 years, they measured 85 cm and 90 cm. Thyroxine
was started for central hypothyroidism. Dynamic GH testing with clonidine
revealed GH deficiency. GH therapy could, however, not be started due to
financial constraints. They returned at 11.5 and 12.5 years of age when
they measured 95 cm and 99 cm (Bone ages- 7.5 years and 8.4 years).
Treatment with GH (0.07 IU/kg/day) for one year resulted in height gains
of 14 cm and 15.5 cm, respectively. They were lost to follow up thereafter
till ages 18 and 19 years when they presented again with short stature and
lack of secondary sexual characters. Heights recorded were 137 cm and 141
cm ( Bone ages-11.2 and 12 yrs). Hormonal profile at ages 18 and 19 years
is given in Table I. Inspite of low cortisol levels, there
was no apparent clinical manifestation of cortisol deficiency. GH therapy
given in the dose of 0.1 IU/kg/day for one year and four months resulted
in 13 cm and 12.5 cm of height gain, respectively. They were advised
regarding intake of steroids during illness and regular telephonic
contacts regarding their well being throughout the rest of follow-up were
maintained. Estrogens initiated at ages 19.5 and 20.5 years resulted in
further height gain. Presently aged 22 and 23 years, they measure 159 cm
and 163 cm (0.1 SD and 0.6 SD, respectively), much above the midparental
height of 149 cm. Prednisolone therapy has been recently initiated for
complaints of excessive sleepiness and lethargy. Two other male siblings
are unaffected.
TABLE I
Clinical and Hormonal Profile of Cases
Family |
Sex |
Age* |
T4 |
TSH |
GH |
Prolactin |
Cortisol |
ACTH |
LH |
FSH |
Height |
Final |
|
|
|
(nm |
(µIU/ |
Peak |
(ng/mL) |
(5-25 |
stimulated |
IU/L |
IU/L |
SDS* |
height |
|
|
|
ol/L) |
mL) |
(ng/ |
|
µg/mL) |
cortisol |
|
|
|
SDS |
|
|
|
|
|
mL) |
|
|
(mcg/mL) |
|
|
|
|
Family 1 |
F |
6 |
30 |
0.32 |
<1 |
3.8* |
2.3* |
– |
1.2* |
2* |
–6.4 |
0.6 |
|
F |
5 |
80 |
1.2 |
<1 |
6.2† |
3.1† |
– |
0.4† |
0.4† |
–6.6 |
0.1 |
Family 2 |
F |
11 |
Low |
0.8 |
0.79 |
6 |
NA |
NA |
0.2* |
0.3* |
–5.4 |
–1.6 |
|
M |
7 |
Low |
1.8 |
0.4 |
3.5 |
2.1** |
12.6** |
0.1† |
0.2† |
–5.1 |
–5.4 |
Test done at †18 years of age; *19 years of age and **21 years of age; NA: not available; *at presentation
|
Family 2: This was a family with two children -
elder girl and younger boy. The girl presented at 11 years of age with
complaints of short stature. Her height was 109 cm at -5.4 standard
deviation score and bone age was 8 yrs. Father’s height was 165 cm and
mother’s was 148 cm. Thyroxine was initiated for central hypothyroidism.
GH dynamic testing performed two months later revealed GH deficiency. GH
therapy however could not be instituted due to financial constraints. She
again presented at 18 years of age with complaints of short stature
(height 139 cm) and absent secondary sexual characters. GH therapy (0.07
IU/kg/day) given for one year resulted in 5.5 cm height gain. Estrogens
were started at 19 years of age. Presently aged 26 years, her height is
152 cm.
The younger brother of the above case presented at 7
years of age with complaints of short stature. His height was 95 cms at
-5.1 SDS and bone age of 4 years . Thyroid profile was normal, GH dynamic
testing revealed GH deficiency. GH therapy could, however, not be
initiated till 14.5 years of age. At this time his height was 121 cm with
a prepubertal phenotype. Thyroxine was initiated for central
hypothyroidism. GH therapy given for one year (0.1 IU/kg/day) resulted in
a poor height gain of 3 cm. Testosterone initiation at 18 years of age
caused a further height gain of 6 cm in one year. Cortisol replacement was
initiated at 21 years of age for symptomatic hyponatremia causing
seizures. Mag-netic Resonance Imaging revealed partial empty sella.
Presently aged 22 years, he is 137 cm tall at 5.4 SD, much below the
midparental height of 163 cm. The genetic analysis of this family revealed
homozygous 13 bp deletion in PROP1 gene (112-124Ä) in both these
siblings(3).
Discussion
In the present report, affected siblings in the two
families had a combination of GH, thyroid stimula-ting hormone (TSH),
gonadotopin and adreno-corticotropin hormone deficiency
(characteristically seen in PROP1 gene defects)(1-4). All these hormonal
deficiencies, however, did not develop at one time. ACTH deficiency became
evident during adulthood in the male sibling; the two female siblings were
asymptomatic inspite of low cortisol levels. Such a silent and delayed
manifestation of corticotropin deficiency in patients with hypo-pituitarism
has been described earlier(4-6). This late onset hypocortisolism due to
Prop 1 gene defects has been attributed to lack of paracrine factors
surrounding the corticotrophs and progressive corticotroph apoptosis(4).
The two sisters who were initiated late on sex steroids
and corticosteroids were taller than their expected height. Some studies
have shown better height outcomes in patients who were initiated on sex
steroids at a late age (around 18 years) compared to those exposed
earlier(14-15 years)(7,8). It is believed that a greater height at onset
of puberty, retarded bone age velocity at pubertal bone age and a
protracted pubertal height gain were possibly responsible for better
results in patients initiated late on sex steroids. Witz, et al.(5)
described a cohort of patients with panhypopituitarism who were
corticotroph deficent. The subgroup that received hydrocortisone (5-10 mg)
had lower growth response to GH compared to those who did not receive
steroid supplementation. There are anecdotal reports of poor growth
response to GH therapy in boys with hypopituitarism compared to girls.
Bosch, et al.(9) described two males who showed a poor
height gain (2-3.5 cm/yr) with GH therapy initiated at 22 and 24 years.
Asteria, et al.(4) described two females with Prop 1
deficiency who had height gain of around 9 cm per year with GH therapy and
had final height exceeding target height. Lerner, et al.(10)
described differential growth responses to GH in males and females with
hypopituitarism, who had received craniospinal irradiation therapy. A
shorter height in males in this report was attributed to a differential
spinal growth in males as compared to the females.
We conclude that patients with combined pituitary
hormone deficiencies may benefit with GH therapy even when they present
late. Steroid replacement should be minimized to ensure an optimal growth
without compromising the need for additional steroids during periods of
stress. We observed that females reached their target height, but final
height was much less in the only male. Reasons for this sexually dimorphic
growth response to GH therapy are unclear and need to be investigated.
Contributors credit: ACA was involved in patient
management and follow-up, manuscript preparation, and editing. BK and ME
were involved in data collection and preparation of manuscript.
Funding: None.
Competing interests: None stated.
References
1. Lissett CA, Shalet SM. Hypopituitarism. In:
Degroot L, J L, editors. Endocrinology., 4th Edition. Philadelphia: WB
Saunders Company; 2001 . p. 289-300.
2. Rosenbloom AL, Almonte AS, Brown MR, Fisher DA,
Baumbach L, Parks JS. Clinical and biochemical phenotype of familial
anterior hypopituitarism from mutation of the PROP1 gene. J Clin
Endocrinol Metab 1999; 84: 50-57.
3. Turton JPG, Mehta A, Raza J, Woods KS, Tiulpakov A,
Cassar J, et al. Mutations within the transcription factor PROP1
are rare in a cohort of patients with sporadic combined pituitary hormone
deficiency(CPHD). Clin Endocrinol 2005; 63: 10-18.
4. Asteria C, Oliveira JH, Abucham J, Beck-Peccoz P.
Central hypocortisolism as part of combined pituitary hormone deficiency
due to mutations of PROP-1 gene. Eur J Endocrinol 2000; 143: 347-352.
5. Witz L, Josefsberg Z, Kaufman H, Laron Z. When
should hydrocortisone therapy be instituted in children with
hypopituitarism? Am J Dis Child 1988; 142: 881-883.
6. Lazar L, Gat-Yablonski G, Kornreich L, Pertzelan A,
Phillip M. PROP-1 gene mutation (R120C) causing combined pituitary hormone
deficiencies with variable clinical course in eight siblings of one Jewish
Moroccan family. Horm Res 2003; 60: 227-231.
7. Bourguignon JP, Vandeweghe M, Vanderschueren- L,
Malvaux P, Wolter R, Caju MD, et al. Pubertal growth and final
height in hypopituitary boys: A minor role of bone age at onset of
puberty. J Clin Endocrinol Metab 1986; 63: 376-382.
8. Birnbacher R, Riedl S, Frisch H. Long-term treatment
in children with hypopituitarism: pubertal development and final height.
Horm Res 1998; 49: 80-85.
9. Van der Werff ten Bosch JJ, Bot A. Growth hormone
and androgen effects in the third decade. Acta Endocrinol Suppl 1986; 279:
29-34.
10. Lerner SE, Huang GJ, McMahon D, Sklar CA, Oberfield
SE. Growth hormone therapy in children after cranial/craniospinal
radiation therapy: sexually dimorphic outcomes. J Clin Endocrinol Metab
2004; 89: 6100-6104.
|
|
|
|